Nuklearmedizin 1981; 20(06): 283-289
DOI: 10.1055/s-0037-1620660
Originalarbeiten – Original Articles
Schattauer GmbH

99mTc-Labelled Compounds Prepared with Sodium Dithionite as Reducing Agent

99mTc-markierte Verbindungen, dargestellt mit Na2S2O4 als Reduktionsmittel
Š. Vilček
1   From the Department of Infectology, University of Veterinary Medicine, and the Institute of Radio ecology and Applied Nuclear Techniques, Košice, Czechoslovakia
,
M. Kalinčák
1   From the Department of Infectology, University of Veterinary Medicine, and the Institute of Radio ecology and Applied Nuclear Techniques, Košice, Czechoslovakia
,
V. Macháň
1   From the Department of Infectology, University of Veterinary Medicine, and the Institute of Radio ecology and Applied Nuclear Techniques, Košice, Czechoslovakia
› Author Affiliations
Further Information

Publication History

Received:08 May 1981

Publication Date:
09 January 2018 (online)

The paper deals with the application of Na2S2O4 as reducing agent in the preparation of 99mTc-labelled compounds. The reduction of pertechnetate can advantageously be carried out in neutral solutions of pH 7. Using this procedure, DTPA, HEDSPA, MDP, gluconate, citrate and trypsin were successfully labelled. In HEDSPA and MDP labelling, a high as cumulation of 99mTc in rat bones (50%) was obtained. In gluconate labelling, under various reaction temperatures, two types of complexes were prepared. Complex I shows a 99mTc biodistribution which is comparable with the kidney diagnosticum 99mTc-Sn-gluconate (24% of 99mTc in kidneys). Complex II, on the other hand, exhibited a reduced affinity of 99mTc to kidneys (2.2%) which, however, increases in bone to 15.4%. The experimental results indicated that Tc(V) is bound in Complex I. In technetium complexing no "mixed complex" is formed, technetium being complexed directly by chelate-forming groups of the labelled compound.

In der Arbeit wird die Verwendung von Na2S2O4 als Reduktionsmittel zur Darstellung von 99mTc-markierten Verbindungen beschrieben. Die Reduktion von Pertechnat kann in neutralen Lösungen (pH 7) vorteilhaft durchgeführt werden. Auf diese Weise wurden DTPA, HEDSPA, MDP, Zitrat, Glukonat und Trypsin erfolgreich markiert. Bei Markierung von HEDSPA und MDP wurde eine hohe Akkumulation von 99mTc in Rattenknochen (50%) gefunden. Bei Markierung von Glukonaten wurden zwei Komplex-Typen bei unterschiedlichen Reaktionstemperaturen dargestellt. Der Komplex I zeigte die in der Nierendiagnostik mit 99mTc-Sn-Glukonat (24% 99mTc in Nieren) vergleichbare Verteilung von 99mTc. Der Komplex II zeigte erniedrigte Affinität von 99mTc zu den Nieren, jedoch eine erhöhte zu den Knochen (15.4%). Die Versuchsergebnisse deuteten darauf hin, daß Tc(V) im Komplex I gebunden vorliegt. Bei der Komplexbildung von Technetium wird der sog. gemischte Komplex nicht gebildet, sondern es wird Technetium durch chelatbildende Gruppen der zu markierenden Verbindung direkt gebunden.

 
  • References

  • 1 Barnes W.E, Colombetti L.G, Arnold J.S. 99mTclabeled complexes of aldehydes and glutamate as cholescin-tigraphic agents. Nucl. Med 14: 330-338 1975;
  • 2 Chervu L.R, Lee H.B, Goyal Q.R, Blaufox M.D. Use of 99mTc-Cu-DTPA complex as a renal function agent. J. nucl. Med 18: 62-66 1977;
  • 3 Cox P.H. 99mTc complexes for skeletal scintigraphy. Physico-chemical factors affecting bone and bone-marrow uptake. Brit. J. Radiol 47: 845-850 1974;
  • 4 Davis M.A, Jones A.G. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletel imaging. Sem. nucl. Med 6: 19-31 1976;
  • 5 Fritzberg A.R, Lyster D.M, Dolphin D.H. Evaluation of formanidine sulfinic acid and other reducing agents for use in the preparation of Tc-99m labeled radiopharmaceuticals. J. nucl. Med 18: 553-557 1977;
  • 6 Galateanu I, Bratu C, Petride A. The reduction of 99mTc-pertechnetate by hydrazine. Radiochem. Radioanal. Lett 28: 95-104 1977;
  • 7 Hauser W, Atkins H.L, Nelson K.G, Richards P. Technetium-99 m DTPA: A new radiopharmaceutical for brain and kidney scanning. Radiology 94: 679-684 1970;
  • 8 Johannsen B, Syhre R. Untersuchungen zur Komple-xierung von 99mTc mit Glukonat. Radiochem. Radioanal. Lett 36: 107-110 1978;
  • 9 Jones A.G, Francis M.D, Davis M. A. Bone scanning: Radionuclidic reaction mechanisms. Sem. nucl. Med 6: 3-18 1976;
  • 10 Kalinčák M, Macháň V, Vilček Š, Balkovský K. A device for automatic measurement of gamma activity distribution on a column. Radioisotopy 19: 779-793 1978;
  • 11 Kalinčák M, Macháň V, Vilček Š. 99mTc-labelled compounds prepared with chrome (II) as reducing agent. Int. J. appl. Radiat. Isotopes 32: 493-499 1981;
  • 12 Macháň V, Vilček Š, Kalinčák M. Possibility of Sn(II) Substitution in 99mTc-Labelled Compounds Preparation. Report LF UPJŠ Košice. 1979
  • 13 Nelson M.P, Melton R.E, Van Wazer J.R. Sodium trimetaphosphate as a bone-imaging agent. I. Animal studies. J. nucl. Med 16: 1043-1048 1975;
  • 14 Pat. ČSSR 203837. 11. 7. 1979.
  • 15 Persson B.R.R, and Darte L. Gel chromatography column scanning for the analysis of 99mTc-labelled compounds. J. Chromatogr 101: 315-326 1974;
  • 16 Persson R. B.R, Liden K. 99mTc-labelled human serum albumin: A study of the labeling procedure. Int. J. appl. Radiat. Isotopes 20: 241-248 1969;
  • 17 Polcin J. Dithionite as Bleaching Agent of Lignified Fibrous Materials. SNTL, Bratislava-Praha. (in Slovak) 1976
  • 18 Vilček Š. Dissertation. LF UPJŠ, Košice. 1981
  • 19 Vilček Š, Macháň V, Kalinčák M, Nicák A. 99mTc-Ti-DTPA: Preparation, control and biological distribution. Int. J. appl. Radiat. Isotopes 30: 673-676 1979;
  • 20 Vilčk Š, Macháň V, Kalinčák M. Preparation of compounds labelled with technetium-99m. Chemické listy 73: 119-135 1979;
  • 21 Vilček Š, Macháň V, Pokorná I, Kalincák M. Compounds labelled with technetium-99m. Radioisotopy 18: 839-919 1977;